Agilent Pathology Solution Receives CE Mark for Device

This new companion diagnostic device has earned a CE Mark from the EU.

This diagnostic device, PD-L1 IHC 22C3, can reveal whether a patient with advanced non-small cell lung cancer is likely to respond to keytruda, an anti-PD-1 therapy.

This diagnostic device was approved for use in the United States last year. — Cynthia Jessup